Results of a Phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri

Results of a Phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri (VBP modified scheme) show that 85.7% of patients given this therapy were NED in Stage IIb versus 54% of a nonrandomized control group given conventional therapy. In Stage IIIb the averages are 66.6% vs. 31% i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 1988-10, Vol.31 (2), p.256-261
Hauptverfasser:	Sardi, Juan E., di Paola, Guillermo R., Giaroli, Adolfo, Sananes, Carlos, Rueda, Nidia Gomez, Cachau, Alberto, Vighi, Susana, Burlando, Silvia
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bleomycin - administration & dosage Chemotherapy Cisplatin - administration & dosage Clinical Trials as Topic Combined Modality Therapy Female Humans Medical sciences Neoplasm Recurrence, Local Neoplasm Staging Pharmacology. Drug treatments Prognosis Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - radiotherapy Uterine Cervical Neoplasms - surgery Vinblastine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Results of a Phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri (VBP modified scheme) show that 85.7% of patients given this therapy were NED in Stage IIb versus 54% of a nonrandomized control group given conventional therapy. In Stage IIIb the averages are 66.6% vs. 31% in the control group. Analysis of the ecographic data has shown that if a critical prechemotherapy volume (120 cm 3) is exceeded, the prognosis is unfavorable, especially in cases treated with radiotherapy as second-line treatment.
ISSN:	0090-8258 1095-6859
DOI:	10.1016/S0090-8258(88)80002-7